Already among the highest in the world, the total cases and peak age of multiple sclerosis in British Columbia are rising, despite a leveling off of new cases. The good news: People are living longer with MS.
Recent research suggests new roles for an old biomarker, autoantibodies to myelin oligodendrocyte glycoprotein, or MOG, a protein component of myelin. Among the new findings, these anti-MOG antibodies are particularly important in pediatric demyelinating diseases.
A fundamental question for people with MS is: What will happen to me? A new study finds a highly variable disease trajectory in people with moderate and advanced MS. The past doesn't seem to predict the future. It adds up to hope that outcomes can be improved, no matter what stage of disease, says medical student Nathaniel Lizak on his preliminary findings.
MSDF interviews Brian Weinshenker MD of the Mayo Clinic about new diagnostic criteria for neuromyelitis optica spectrum disorder and how it differs from MS. The new criteria build upon and broaden the definition of NMO.